Alpha-9 Oncology
Brendan Grosse is a seasoned talent acquisition professional currently serving as the Senior Manager, Talent Partner at Alpha-9 Oncology since September 2024. Prior roles include Senior Contract Recruiter at TScan Therapeutics, Talent Partner at Tessera Therapeutics, and Talent Acquisition Partner at Finch Therapeutics, where contributions focused on clinical studies related to microbiome health. Brendan's experience also encompasses recruitment at AP Biosciences and Medicus Healthcare Solutions, alongside a background in patient care in fitness and rehabilitation settings. Educational achievements include a Master’s degree in Health and Wellness Management from Merrimack College and a Bachelor of Applied Science in Kinesiology and Exercise Science from the University of Massachusetts Amherst.
This person is not in any teams
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.